ArticleDermatology and therapy2015
Primary care review of actinic keratosis and its therapeutic options: a global perspective.
Article in Dermatology and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Genome-wide association study of actinic keratosis identifies new susceptibility loci implicated in pigmentation and immune regulation pathways.Communications biology · 2022Pooled it
- Treatment of actinic cheilitis: a systematic review.Clinical oral investigations · 2019Pooled it
- Review
- Holistic Value Assessment of Tirbanibulin for Actinic Keratosis: European Multi-Criteria Decision Analysis.Dermatology and therapy · 2026Article
- Artificial Intelligence-Assisted Dermatologic Screening: Epidemiology and Clinical Features of Basal Cell Carcinoma, Squamous Cell Carcinoma, Seborrheic Keratosis and Actinic Keratosis.Bioengineering (Basel, Switzerland) · 2025Review
- Cryotherapy-Induced Full-Thickness Digital Frostbite Injury Reconstructed With Reverse Cross-Finger Flap.Journal of hand surgery global online · 2025Article
- Evaluation of Actinic Keratosis as a Risk Factor for Subsequent Nonskin Cancer Risk.JID innovations : skin science from molecules to population health · 2025Article
- Actinic keratosis: comprehensive review of current treatments and emerging therapeutic innovations.Postepy dermatologii i alergologii · 2025Review
- Article
- From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments.Frontiers in immunology · 2025Review
- Natural Compounds in Non-Melanoma Skin Cancer: Prevention and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Smartphone-based dual radiometric fluorescence and white-light imager for quantification of protoporphyrin IX in skin.Journal of biomedical optics · 2023Article
- A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations.Dermatology and therapy · 2023Review
- Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project.Acta dermato-venereologica · 2023Article
- Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.International journal of molecular sciences · 2023Review
- Attitudes among dermatologists regarding actinic keratosis treatment options.Dermatology reports · 2022Article
- Actinic Keratoses (AK): An Exploratory Questionnaire-Based Study of Patients' Illness Perceptions.Current oncology (Toronto, Ont.) · 2022Article
- Complexation of 5-Fluorouracil withToxics · 2022Article
- Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinic keratosis (AK) is a common skin condition caused by long-term sun exposure that has the potential to progress to non-melanoma skin cancers. The objective of this review is to examine the therapeutic options and management of AK globally, particularly in Australia, Canada, and the United Kingdom. Despite its potentially malignant nature, general awareness of AK is low, both in the general population and in the primary health care setting, especially in countries with low incidence. There is no standard therapeutic strategy for AK; it is treated through a variety of lesion-directed or field-directed therapies or a combination of both. A variety of treatment options are used depending on the experience of the primary care physician, the pathology of the lesion, and patient factors. Studies have shown that the physicians do not always use the optimal treatment option because of a lack of knowledge. The higher incidence of AK in fair-skinned people in Australia has resulted in well-established management strategies and guidelines for its treatment, compared with countries with lower incidence. It is essential to raise the awareness of AK because of its potential to progress to invasive squamous cell carcinoma. Primary care physicians are often the first to see this condition in their patients and are perfectly placed to educate the public and raise awareness. It is therefore desirable that their education and knowledge about AK and its treatment are up to date.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.